HOME >> MEDICINE >> NEWS
Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, December 13 -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that the US Food & Drug Administration (FDA) has approved EQUETRO(TM) (extended-release carbamazepine capsules), previously known as SPD417, for the treatment of patients with Bipolar Disorder, ten months after submission.

Bipolar Disorder is one of the six leading mental disorders worldwide, according to the World Health Organization.[i] Each year, it is estimated that more than 2 million American adults[ii], [iii], about 1 percent of the population age 18 and older,[iv] are afflicted with Bipolar Disorder, also known as manic depression. Of the 750,000 currently diagnosed, about 650,000 are treated. The bipolar market in the United States is currently valued at about US$1.9bn and is expected to grow to $2.4bn by 2007(++).

Bipolar Disorder is characterized by episodes of mania and depression, with periods of normal mood in between. The disorder can have devastating effects on an individual's life, although proper diagnosis and earlier treatment can usually alter the course of the illness.

EQUETRO significantly reduces the manic symptoms in Bipolar patients. Additionally, in clinical trials, patients treated with the product demonstrated no clinically significant weight gain or increase in blood glucose levels, thereby creating an effective tolerability profile(+). The unique three-bead extended release delivery system of Equetro provides for convenient administration as well. Available in 100, 200 and 300mg dosage strengths, it is the only carbamazepine formulation proven effective for patients with Bipolar Disorder.

EQUETRO has a formulation patent that runs until 2011 and will have three years market exclusivity under the US Hatch-Waxman Act. It will be available for prescribing in the US in the first quarter of 2005.

Matthew Emmens, Chief Executive of Shire commented: "Bi
'"/>

Contact: Matthew Cabrey, Shire Pharmaceuticals plc
484-595-8248
Porter Novelli
13-Dec-2004


Page: 1 2

Related medicine news :

1. Shire receives approvable letter for adult ADDERALL XR(R) from FDA
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... ... , ... Autopsies don’t lie. They report the causes of death as ... harms the heart. It increases risks of heart attack and death. Autopsies ... damage occurs. , An August 1, 2019 article in U.S. News ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... the team. Dr. Hesano is an understanding, caring and highly skilled Obstetrician/Gynecologist. ... obstetrical medicine. Dr. Hesano strives to ensure that each visit is comfortable, patient-focused, ...
(Date:9/9/2019)... ... September 09, 2019 , ... ST Engineering ... International will integrate the iDirect iQ 200 Board and the latest Evolution® software ... for first responders. The iQ 200 Board will enable the HARRIER solution to ...
(Date:9/9/2019)... ... September 09, 2019 , ... On ... organization-wide policy focusing on a diabetes-language movement (#LanguageMatters) to include oral and written ... non-judgmental, free from stigma, respectful and inclusive, empowering, and person-centered (to include care ...
(Date:9/8/2019)... ... 2019 , ... The reviews from patients of ABM Medical Clinic who have ... and pain free fat loss system, has patients booking their sessions and recommending this ... uses state of the art technology incorporating radio frequency and heat to rid the ...
Breaking Medicine News(10 mins):
(Date:9/11/2019)... ... September 11, 2019 , ... HOLLOWAY AMERICA, a leading manufacturer ... beverage to pharma and chemical, recently announced it will showcase its problem-solving vessels and ... , HOLLOWAY AMERICA’s first stop will be at ISPE San Diego’s 27th Life ...
(Date:9/11/2019)... ... 2019 , ... Pivot Point Consulting is excited to announce ... Partnerships team. Maris brings two decades of experience with Cerner—leading both sales ... as a Technical Implementation Leader representing the Technical Engagement Leader community. , Pivot ...
(Date:9/9/2019)... , ... September 09, 2019 , ... ... Shoreline Periodontics & Dental Implants host the latest course in their Synergy Study ... Mystic, CT and features guest speaker Dr. Peter Barndt. Synergy Study Club brings ...
Breaking Medicine Technology:
Cached News: